Image courtesy of Canva
Kansas Attorney General Kris Kobach announced a nearly $720 million nationwide settlement with eight pharmaceutical companies accused of contributing to the opioid crisis. Kansas is set to receive about $5.7 million from the agreement.
The companies and their financial commitments include:
- Mylan (now Viatris): $284.4 million over nine years
- Hikma: $95.8 million over one to four years
- Amneal: $71.7 million over 10 years
- Apotex: $63.6 million in one year
- Indivior: $38 million over four years
- Sun: $30.9 million over one to four years
- Alvogen: $18.6 million in one year
- Zydus: $14.8 million in one year
Beyond monetary payments, several companies must offer free products or equivalent cash. Seven companies (excluding Indivior) are banned from marketing opioids, making high-dose pills, and must monitor suspicious orders. Indivior, while barred from producing or selling opioids for 10 years, may continue offering treatments for opioid use disorder.
North Carolina, California, Colorado, Illinois, New York, Oregon, Tennessee, Utah, and Virginia attorneys general offices negotiated the settlements on behalf of Kansas and several other states.
